Alivus Life Sciences Ltd (ALIVUS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003513, "name": "Alivus Life", "stock_name": "Alivus Life", "full_name": "Alivus Life Sciences Ltd", "name_url": "stocks-analysis/alivus-life", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "983.10", "chg": 14.1, "chgp": "1.46%", "dir": 1, "prev_price": "969.00", "mcapval": "11,975.00 Cr", "mcap": "Small Cap", "scripcode": 543322, "symbol": "ALIVUS", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE03Q201024", "curr_date": "Mar 25", "curr_time": "", "bse_nse_vol": "1.17 lacs", "exc_status": "Active", "traded_date": "Mar 25, 2026", "traded_date_str": "2026 03 25", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alivus-life-1003513-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Alivus Life Sciences Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-technical-momentum-shifts-amid-mixed-market-signals-3909247", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AlivusLifeScien_technicaldot_3909247.png", "date": "2026-03-24 08:04:48", "description": "Alivus Life Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent downgrade in daily moving averages and mixed monthly indicators, the stock’s weekly technicals suggest pockets of bullishness, reflecting a complex interplay of market forces as it navigates current price pressures." }, { "title": "Alivus Life Sciences Gains 0.41%: 2 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-gains-041-2-key-factors-driving-the-week-3905115", "imagepath": "", "date": "2026-03-21 12:01:09", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>16 Mar:</strong> Valuation shifts to fair amid strong sector performance</p>\n <p><strong>17 Mar:</strong> Stock rebounds with 1.22% gain following valuation update</p>\n <p><strong>19 Mar:</strong> Technical momentum shifts signal mixed outlook</p>\n <p><strong>20 Mar:</strong> Stock closes week higher at Rs.948.90 (+2.37%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.925.70</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.94..." }, { "title": "Alivus Life Sciences Ltd Technical Momentum Shifts Signal Mixed Outlook", "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-technical-momentum-shifts-signal-mixed-outlook-3899758", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AlivusLifeScien_technicaldot_3899758.png", "date": "2026-03-19 08:03:07", "description": "Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and others, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector." }, { "title": "Alivus Life Sciences Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-3896205", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AlivusLifeScien_mojoScore_3896205.png", "date": "2026-03-17 10:10:45", "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of its performance and prospects." }, { "title": "Alivus Life Sciences Ltd Valuation Shifts to Fair Amid Strong Sector Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-valuation-shifts-to-fair-amid-strong-sector-performance-3892674", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AlivusLifeScien_valuationdot_3892674.png", "date": "2026-03-16 08:01:23", "description": "Alivus Life Sciences Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of early 2026. Despite this adjustment, the small-cap pharmaceutical and biotechnology firm continues to demonstrate solid operational metrics and a resilient market performance relative to broader indices, prompting a reassessment of its price attractiveness within a sector characterised by elevated multiples." }, { "title": "Alivus Life Sciences Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-3875562", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AlivusLifeScien_mojoScore_3875562.png", "date": "2026-03-06 10:10:44", "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing." }, { "title": "Alivus Life Sciences Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-3850320", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AlivusLifeScien_mojoScore_3850320.png", "date": "2026-02-23 10:11:12", "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing." }, { "title": "Alivus Life Sciences Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-3850328", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AlivusLifeScien_mojoScore_3850328.png", "date": "2026-02-22 10:10:41", "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 February 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Alivus Life Sciences Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/alivus-life-sciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3846305", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AlivusLifeScien_valuationdot_3846305.png", "date": "2026-02-19 08:02:18", "description": "Alivus Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven by improved price-to-earnings and price-to-book ratios relative to its historical averages and peer group. This change has prompted an upgrade in its Mojo Grade from Sell to Hold, reflecting a more favourable outlook amid a challenging pharmaceutical sector backdrop." } ], "total": 265, "sid": "1003513", "stock_news_url": "https://www.marketsmojo.com/news/alivus-life-sciences-1003513" }, "announcements": [ { "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015", "datetime": "21-Mar-2026", "details": "Kindly refer attachment.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "12-Mar-2026", "details": "Disclosure under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meeting", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "06-Mar-2026", "details": "Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 - Intimation of Investors/Analyst Meeting", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Alivus Life Sciences Ltd has declared <strong>250%</strong> dividend, ex-date: 01 Sep 25", "dt": "2025-09-01", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

16 Mar: Valuation shifts to fair amid strong sector performance

17 Mar: Stock rebounds with 1.22% gain following valuation update

19 Mar: Technical momentum shifts signal mixed outlook

20 Mar: Stock closes week higher at Rs.948.90 (+2.37%)

Read full news article

Alivus Life Sciences Ltd Technical Momentum Shifts Signal Mixed Outlook

2026-03-19 08:03:07

Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and others, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-03-17 10:10:45

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of its performance and prospects.

Read full news article

Alivus Life Sciences Ltd Valuation Shifts to Fair Amid Strong Sector Performance

2026-03-16 08:01:23

Alivus Life Sciences Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of early 2026. Despite this adjustment, the small-cap pharmaceutical and biotechnology firm continues to demonstrate solid operational metrics and a resilient market performance relative to broader indices, prompting a reassessment of its price attractiveness within a sector characterised by elevated multiples.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-03-06 10:10:44

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-02-23 10:11:12

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Alivus Life Sciences Ltd is Rated Hold

2026-02-22 10:10:41

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 February 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Alivus Life Sciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-02-19 08:02:18

Alivus Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven by improved price-to-earnings and price-to-book ratios relative to its historical averages and peer group. This change has prompted an upgrade in its Mojo Grade from Sell to Hold, reflecting a more favourable outlook amid a challenging pharmaceutical sector backdrop.

Read full news article